Genome Web Breaking News
- Cancer Prognoses Informed by Module-Based Approach, Study Finds
- People in the News at Illumina, Centogene, BioSkryb
- New Products Posted to GenomeWeb: Bio-Rad, BD, Analytik Jena, BioMérieux
- Study Reveals New Details About Genetics of Major Cause of Female Infertility
- Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer
Stat
- STAT+: Turkish court hands Novartis and Roche a rare win over their efforts to promote an eye treatment
- STAT+: Up and down the ladder: The latest comings and goings
- STAT+: Pharmalittle: ALS Association and its chapters battle over money and priorities; eye drops recalled over links to drug-resistant infections
- Opinion: Public health layoffs and tech layoffs: a world of difference
- STAT+: They were the 10% left out of life-changing treatments. Now these cystic fibrosis patients may finally get help
NYT science news
- What’s the Correct Color of Bees? In Austria, It’s a Toxic Topic.
- Brazil Says It’s Started Sinking an Old Warship, Hazardous Material and All
- How to Stay Safe in Extreme Cold Weather
- New Form of Ice Discovered Unexpectedly During Experiment
- These Extinct Elephants Were Neanderthals’ ‘Biggest Calorie Bombs’
Fierce Biotech
- 4D in unknown dimension as FDA slaps hold on Fabry gene therapy trial
- Siemens' Varian lands US, EU nods for tool to image tumors in seconds during radiation treatments
- Bruised by high profile cancer setbacks, Sanofi CEO plots early-stage path ‘back to the magic’
- Abbott collects European, U.S. clearances for heart ablation catheters
- Boston Scientific found guilty of infringing on drug-eluting stent patent, fined $42M
Fierce Medical Devices
- Siemens' Varian lands US, EU nods for tool to image tumors in seconds during radiation treatments
- Abbott collects European, U.S. clearances for heart ablation catheters
- Boston Scientific found guilty of infringing on drug-eluting stent patent, fined $42M
- White House expands Cancer Moonshot programs with screening, AI partnerships
- Despite COVID testing crash and stagnant base business, BD brightens 2023 outlook